Our study was unique in focusing on the trends in a cancer-screening test at an urban hospital in an underserved population where the risk of prostate cancer is on average higher than surrounding populations.22–24 Such patients may be more adversely affected by declining PSA screening than lower at-risk populations. The gene discussed is KLK3; the disease is prostate carcinoma.